All Eyes on Nutriband Inc. (NASDAQ: NTRB) Tomorrow—Last Time, It Moved Approx. 126% in 48 Hours

*Sponsored by Nutriband Inc. Market Crux Exclusive! All Eyes on Nutriband Inc. (NASDAQ: NTRB) Tomorrow (2/7/2025)—Last Time, It Moved Approx. 126% in 48 Hours The Last Time We Covered Nutriband Inc. (NASDAQ: NTRB) It Moved Approximately 126% In Under 48 Hours. Key Highlights On Nutriband Inc. (NASDAQ: NTRB): Low Float & Market Recognition : Under 5.1M Shares In The Float, With An Approx. 202% Move In One Week This January. Technical Strength: Trending Above Key Moving Averages, Signaling Momentum Potential. Insider Confidence: Over 54% Insider Ownership As Of 2/6/2025. Breakthrough Innovation: Advancing Abuse-Deterrent AVERSA™ Technology With Regulatory Milestones Ahead. Global Expansion: Patents In 46 Countries, Plus Recent  U.S. Trademark Approvals. Analyst Coverage: Noble Capital’s Robert LeBoyer Set A $13 Target, Suggesting Over 103% Upside Potential. Consider Adding Nutriband Inc. (NASDAQ: NTRB) to  Your Radar Tomorrow… February 6, 2025 Dear Reader, After today’s biotech profile moved approx. 17% and yesterday’s moved approx. 19%—both in less than 24 hours—we’re setting our sights on another little-known company in the same space.  This under-the-radar pharma company turned heads when we covered it a few weeks ago, and now it’s back in focus for all the right reasons. If you’ve been following along, you already know this name. Let’s not waste time. Nutriband Inc. (NASDAQ: NTRB) is topping our watchlist tomorrow morning. Last time we covered (NTRB), it made an approx. 126% move in under 48 hours.  That was only a few weeks ago. And with momentum building again, we’ll have all eyes on (NTRB) tomorrow. Keep reading to see why… Let’s call it like it is—few biotech companies are pushing boundaries quite like Nutriband Inc. (NASDAQ: NTRB). While others stick to tired formulas and incremental changes, Nutriband Inc. (NASDAQ: NTRB) is establishing itself as a leader in the development of advanced transdermal technologies, addressing some of the most critical challenges in healthcare today. With a low float, of less than 5.1M shares listed, we’re keeping a close eye on Nutriband Inc. (NASDAQ: NTRB) because this scarcity could lead to the potential for significant swings if demand begins to change. In fact, Nutriband Inc. (NASDAQ: NTRB) recently moved approximately 202% in one week, from $3.90 on January 16th to $11.78 on January 23, 2025. Currently trending above several key moving averages, Nutriband Inc. (NASDAQ: NTRB) is showing strong technical momentum.  With its 20-day moving average at $6.44, 50-day at $5.21, 100-day at $5.57, and 200-day at $5.42, (NTRB) is currently trending above all long-term indicators tracked by Barchart—a bullish signal that could suggest further upside potential.  Additionally, its year-to-date moving average of $6.15 reinforces the notion that (NTRB) has been maintaining strength despite broader market fluctuations. Backing this momentum, insider ownership stands at over 54% as of 2/6/2025—an exceptionally strong vote of confidence from those who know the company best. With more than half of all shares held by insiders, leadership is signaling long-term commitment and belief in future growth. This combination of technical strength and a market cap under $75M, could position (NTRB) as a high-growth candidate compared to larger players in the same space. Just over two weeks ago, Noble Capital’s Robert LeBoyer initiated coverage on (NTRB) with a Bullish Rating and a $13 target, which suggests over 103% upside potential from today’s $6.39 level. At the heart of this optimism is Nutriband Inc. (NASDAQ: NTRB)’s Phase 1 clinical trial, which is expected to showcase the effectiveness of its abuse-deterrent technology, setting up for an NDA filing by late 2025 and potential FDA approval in 2026. With a clear roadmap ahead and momentum at its back, Nutriband Inc. (NASDAQ: NTRB) is earning attention for all the right reasons. In a year where many companies struggled to stay relevant, (NTRB) refused to slow down—doubling down on its strategy, solidifying its position, and delivering results that speak for themselves. Trailblazing with AVERSA™ Fent-a-nyl Nutriband Inc. (NASDAQ: NTRB)’s crown jewel, AVERSA™ Fent-a-nyl, has redefined what’s possible in abuse-deterrent therapeutics.  This groundbreaking transdermal patch is designed not just to combat misuse but to revolutionize patient safety across the board.  With support from Kindeva Dr-ug Delivery, Nutriband Inc. (NASDAQ: NTRB) made significant headway in 2024: Completed pivotal validation studies, advancing the product closer to market readiness. Established a clear regulatory path for its New Application (NDA) submission in 2025, relying on a streamlined single Phase 1 Human Abuse Potential study. This isn’t just a pipe dream, either. If approved, AVERSA™ Fent-a-nyl is projected to rake in U.S. sales of $80M to $200M annually—a staggering testament to its market potential. Nutriband Inc. (NASDAQ: NTRB) Expands Global Reach with  Patents in 46 Countries Nutriband Inc. (NASDAQ: NTRB) isn’t just thinking local; they’re playing on a global stage. With patent approvals in China and Hong Kong, the company now boasts intellectual property coverage in 46 countries.  A U.S. Notice of Allowance for the AVERSA™ trademark further solidified their footing, giving competitors a clear signal: Nutriband Inc. (NASDAQ: NTRB) is here to lead. Strategic Fiscal Growth Numbers don’t lie.  Nutriband Inc. (NASDAQ: NTRB) reported record-breaking revenues in 2024, with their contract manufacturing arm, Pocono Pharma, leading the charge: A Q3 revenue of over $645k, representing a 51% year-over-year increase. Strengthened financial reserves, courtesy of $8.4M in fresh capital from a private placement. This fiscal foundation gives Nutriband Inc. (NASDAQ: NTRB) the firepower it needs to push AVERSA™ Fent-a-nyl over the finish line while continuing to innovate. Nutriband Inc. (NTRB) Gears Up for FDA Submission—Could AVERSA™ Fent-a-nyl Hit the Market in 2025? Regulatory Milestones Await: The centerpiece of Nutriband Inc. (NASDAQ: NTRB)’s 2025 ambitions is the NDA submission for AVERSA™ Fent-a-nyl. With pivotal data in hand and no need for extended Phase 2 or Phase 3 trials, the company anticipates an expedited review process.  Translation? AVERSA™ Fent-a-nyl could be on the market before the year is out. Scaling for Success: Preparation for commercialization is already underway. Nutriband Inc. (NASDAQ: NTRB) is scaling its partnership with Kindeva Dr-ug Delivery to ensure manufacturing excellence.  Simultaneously, the company is laying the groundwork for international licensing and distribution agreements, proving that they aren’t content with U.S. dominance—they’re going global. A Pipeline with Potential: AVERSA™ Fent-a-nyl is just the beginning. Nutriband Inc. (NASDAQ: NTRB) is also advancing AVERSA™ Buprenorphine and exploring additional transdermal applications.  If these developments live up to their promise, Nutriband Inc. (NASDAQ: NTRB) could unlock an entirely new revenue stream, with AVERSA™ Buprenorphine alone estimated to generate $130M annually. Nutriband (NTRB) Expands Retail Presence with Target, Walmart, Walgreens & CVS Partnerships Nutriband Inc. (NASDAQ: NTRB) isn’t relying on just one path to success. The company’s manufacturing divisions—Pocono Pharma and Active Intelligence—are building momentum on multiple fronts. Expanded partnerships with retail giants like Target, Walmart, Walgreens, and CVS. Delivered innovative kinesiology and consumer health products, including an exclusive supplier agreement with Fit For Life Group, which represents Adidas, Reebok, and New Balance. Launched a Mosquito Repellent Patch in Costa Rica, marking their entry into the lucrative Central and South American markets. On the Brink of Transformation—Nutriband (NTRB) Sets the Stage for Major Growth Potential There's no sugarcoating it—the opi-oid crisis is one of the most pressing public health emergencies of our era. Nutriband Inc. (NASDAQ: NTRB) isn’t just talking about solutions; they’re delivering them.  The AVERSA™ technology represents a paradigm shift in patient safety, offering a tangible way to reduce misuse, accidental exposure, and diversion of high-risk therapeutics. As CEO Gareth Sheridan aptly put it, Nutriband Inc. (NASDAQ: NTRB) is “on the brink of a transformative period in its history.”  And he’s not wrong.  The company has not only set the stage for regulatory and commercial success but also laid a solid foundation for long-term growth. Innovation Meets Impact: Nutriband (NTRB) Is Reshaping Healthcare Nutriband Inc. (NASDAQ: NTRB) isn’t just playing in the big leagues—it’s rewriting the rulebook. With AVERSA™ Fent-a-nyl on the cusp of commercialization, an ever-expanding pipeline, and strong fiscal performance, the company is positioning itself to drive innovation and make a real-world impact in healthcare. For those watching from the sidelines, here’s your wake-up call.  Nutriband Inc. (NASDAQ: NTRB) is not just about innovation; it’s about making a meaningful impact. See Nutriband Inc. (NASDAQ: NTRB)’s corporate presentation here. 5 Reasons Why Nutriband Inc. (NASDAQ: NTRB) is #1 On Our Watchlist Tomorrow… 1. Low Float & Market Recognition: With under 5.1M shares in the float, Nutriband Inc. (NASDAQ: NTRB) has shown its potential for significant swings, including an approx. 202% move in a single week this January. 2. Technical Strength: Currently trending above multiple key moving averages, signaling potential for continued momentum. 3. Strong Insider Commitment:  As of 2/6/2025, over 54% of shares are held by insiders, reflecting long-term confidence from those closest to the company. 4. Breakthrough Innovation: With AVERSA™ – Nutriband Inc. (NASDAQ: NTRB) is advancing abuse-deterrent technology with regulatory milestones on the horizon. 5. Expanding Global Presence: With patents in 46 countries and recent U.S. trademark approvals, Nutriband Inc. (NASDAQ: NTRB) is building a worldwide footprint. Consider Adding Nutriband Inc. (NASDAQ: NTRB) to  Your Radar Tomorrow… Let’s call it like it is—few biotech companies are pushing boundaries quite like Nutriband Inc. (NASDAQ: NTRB). While others recycle the same formulas, (NTRB) is setting new standards with its AVERSA™ technology, a rapidly expanding pipeline, and global patent protection to match. With a low float, strong insider ownership, and technicals lining up, (NTRB) isn’t just another company on a watchlist—it’s a profile that keeps demanding attention. And if recent history is any indication, (NTRB)’s approx. 202% move in just one week last month proves that when momentum picks up, it doesn’t move quietly. Could we be in for another round? We’ll be watching closely. All eyes are on (NTRB) tonight. Take a look before tomorrow morning. Keep an eye out for my early morning update. Have a good night. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 02/06/2025 and ending on 02/07/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid fifteen thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither Headline Media LLC, TD Media LLC and their members own shares of (NTRB:US). Please see important disclosure information here: https://marketcrux.com/disclosure/ntrb/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice